Growing prevalence of sports injuries, and elbow tendon bumps, joint pain are the key factors that have urged the advent of tennis elbow market. In the next few years the demand for tennis elbow treatment is expected to increase significantly in the emerging economies such as China and Canada. Geriatric population is growing with the rising global population, and rising sports events are leading to increase in number of sports injuries and these are expected to boost the industry in the coming years.
The treatments studies for analyzing the overall lateral epicondylitis market are painkillers and NSAIDs, corticosteroid injections shock wave therapy surgery, and equipment and other products. Market size and forecast for each of these segments for the period 2014-2022 are provided in this study along with respective CAGRs for the forecast period 2016-2022. This report also highlights information about major clinical trial candidates under scrutiny for lateral epicondylitis treatment. These candidates are categorized corresponding to their trial phase, namely phase I, phase II and phase III.
Geographically, the global lateral epicondylitis market is studied for the following regional markets:
1. North America
a. U.S.
b. Canada
2. Europe
a. U.K.
b. Germany
c. Rest of Europe
3. Asia-Pacific
a. Japan
b. China
c. Rest of Asia-Pacific
4. Middle East and Africa
5. Latin America
Market size and forecast for these regional and country level markets are presented in this study for the period 2014-2022. Market growth rates for the forecast period 2016-2022 are also included in this report, considering 2015 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global lateral epicondylitis market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global lateral epicondylitis market. This report concludes with company profiles section that highlights major information about the key players engaged in lateral epicondylitis market.
CHAP 1. PREFACE
1.1. REPORT SCOPE AND DESCRIPTION
1.2. RESEARCH METHODOLOGY
1.2.1. PHASE I – SECONDARY RESEARCH
1.2.2. PHASE II – PRIMARY RESEARCH
1.2.3. PHASE III – EXPERT PANEL REVIEW
CHAP 2. EXECUTIVE SUMMARY
2.1. GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET SNAPSHOT
CHAP 3. GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET ANALYSIS
3.1. LATERAL EPICONDYLITIS TREATMENT MARKET OVERVIEW
3.2. MARKET INCLINATION INSIGHTS
3.2.1. SHOCKWAVE THERAPY: TREATMENT TYPE GROWING WITH A REMARKABLE RATE
3.2.2. OTHER TREATMENT TYPES SUCH AS PRP, SPLINT ELBOW BRACE, ICE PACKS, ETC. EXPECTED TO HOLD THE LARGEST MARKET SHARE.
3.3. MARKET DYNAMICS
3.3.1. MARKET DRIVERS
3.3.1.1. RISING SPORTS INJURIES
3.3.1.2. RISING PATIENT AWARENESS
3.3.1.3. RISING GERIATRIC POPULATION
3.3.2. RESTRAINTS
3.3.2.1. SIDE EFFECTS OF THE TREATMENT
3.3.2.2. EARLY RETIREMENT AGE OF PLAYERS
3.3.3. CHALLENGES
3.3.3.1. SLOW RESPONDING COMMERCIALIZATION OF NEW & EFFECTIVE THERAPIES
3.3.4. OPPORTUNITIES
3.3.4.1. TECHNOLOGICAL ADVANCEMENTS:
3.3.5. ATTRACTIVE INVESTMENT PROPOSITION, 2015
3.3.6. MARKET POSITIONING OF KEY MANUFACTURES
CHAP 4. GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET, BY TREATMENT TYPE, 2014 – 2022 (USD MN)
4.1. OVERVIEW
4.2. PAINKILLERS AND NSAIDS
4.3. CORTICOSTEROID INJECTIONS
4.4. SHOCK WAVE THERAPY
4.5. SURGERY
4.6. EQUIPMENT AND OTHER PRODUCTS
CHAP 5. GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET, BY PIPELINE TREATMENTS ASSESSMENT (QUALITATIVE INFORMATION)
5.1. OVERVIEW
5.2. PHASE I
5.3. PHASE II
5.4. PHASE III
CHAP 6. GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY GEOGRAPHY 2014 – 2022 ($ MILLION)
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. U.S.
6.2.2. CANADA
6.3. EUROPE
6.3.1. U.K.
6.3.2. GERMANY
6.3.3. REST OF EUROPE
6.4. ASIA-PACIFIC
6.4.1. JAPAN
6.4.2. CHINA
6.4.3. REST OF ASIA-PACIFIC
6.5. MIDDLE EAST AND AFRICA
6.6. LATIN AMERICA
CHAP 7. PROFILES
7.1. ARTHREX
7.2. TEIKOKU PHARMA
7.3. SEIKAGAKU CORPORATION
7.4. UNIPHAR GROUP
7.5. SMITH & NEPHEW
7.6. OTHERS
List of Tables
TABLE 1 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET 2014-2022 ($ MILLION) TABLE 2 SIDE-EFFECTS CAUSED BY NSAIDS
TABLE 3 SIDE EFFECTS OF CORTICOSTEROIDS
TABLE 4 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY TREATMENT TYPE 2014–2022 ($ MILLION)
TABLE 5 STUDY OF DRUG TRIALS RELATED TO LATERAL EPICONDYLITIS
TABLE 6 NORTH AMERICA LATERAL EPICONDYLITIS TREATMENT MARKET REVENUE ($ MILLION)
TABLE 7 SPORTS PARTICIPANTS IN U.S.
TABLE 8 SPORTS & ACTIVITIES PARTICIPANTS IN CANADA OF 3-17YEARS
TABLE 9 EUROPE LATERAL EPICONDYLITIS TREATMENT REVENUE ($ MILLION)
TABLE 10 PARTICIPATION OF U.K.IN SPORTS
TABLE 11 EUROPE LATERAL EPICONDYLITIS TREATMENT REVENUE ($ MILLION)
List of Figures
FIGURE 1 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET RESEARCH METHODOLOGY
FIGURE 2 MARKET SNAPSHOT: LATERAL EPICONDYLITIS TREATMENT MARKET
FIGURE 3 BENEFITS OF SHOCK WAVE THERAPY
FIGURE 4 OTHER TREATMENT TYPES (PRP, SPLINT ELBOW BRACE, ICE PACKS) MARKET 2014-2022
FIGURE 5 NUMBER OF INJURIES BY SPORTS AMONG CHILDREN AGES 19 AND UNDER, 2014
FIGURE 6 CHILDREN AGEING 5 TO 14 HOSPITALIZED DUE TO SPORTS INJURY (U.S. 2014)
FIGURE 7 PERCENTAGE OF POPULATION AGED OVER 60 YEARS OR OVER BY REGION IN 2015
FIGURE 8 PROPORTION OF POPULATION AGED 60 OR OVER IN 2014
FIGURE 9 COMMONLY USED NSAIDS, CORTICOSTEROIDS
FIGURE 10 ATTRACTIVE INVESTMENT PROPOSITION
FIGURE 11 TOP 3 PLAYERS OF GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET
FIGURE 12 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY PAINKILLERS & NSAIDS 2014-2022 ($ MILLION)
FIGURE 13 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY CORTICOSTEROID INJECTIONS 2014-2022 ($ MILLION)
FIGURE 14 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY SHOCK WAVE THERAPY 2014-2022 ($ MILLION)
FIGURE 15 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY SURGERY 2014-2022 ($ MILLION)
FIGURE 16 GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET BY EQUIPMENT AND OTHER PRODUCTS 2014-2022 ($ MILLION)
FIGURE 17 STAGES OF LATERAL EPICONDYLITIS TREATMENT PIPELINE
FIGURE 18 TANEZUMAB DETAILS
FIGURE 19 NORTH AMERICA REVENUE GENERATION IN LATERAL EPICONDYLITIS TREATMENT MARKET ($ MILLION)
FIGURE 20 PERCENTAGE OF POPULATION AGED 60 YEARS OR ABOVE IN NORTH AMERICA
FIGURE 21 MARKET SHARE OF NORTH AMERICA IN THE GLOBAL LATERAL EPICONDYLITIS TREATMENT MARKET.
FIGURE 22 COMPARATIVE ANALYSIS OF THE U.S.A. AND CANADA LATERAL EPICONDYLITIS (TENNIS ELBOW) MARKET 2015-2022 ($MILLION)
FIGURE 23 NORTH AMERICA LATERAL EPICONDYLITIS TREATMENT MARKET BY TREATMENT TYPE IN 2015
FIGURE 24 U.S. LATERAL EPICONDYLITIS TREATMENT MARKET 2014-2022 ($ MILLION)
FIGURE 25 POPULATION AGED 65 AND ABOVE IN UNITED STATES 2014-2022 (MILLION)
FIGURE 26 CANADA LATERAL EPICONDYLITIS TREATMENT MARKET, 2014-2022 ($MILLION)
FIGURE 27 EUROPE LATERAL EPICONDYLITIS TREATMENT MARKET 2014-2022 ($ MILLION)
FIGURE 28 NSAIDS CONSUMPTION BY REGIONS IN 2015
FIGURE 29 UK LATERAL EPICONDYLITIS TREATMENT MARKET, 2014-2022 ($MILLION)
FIGURE 30 GERMANY LATERAL EPICONDYLITIS MARKET, 2014-2022 ($MILLION)
FIGURE 31 GERMANY DEMOGRAPHICS (2015)
FIGURE 32 REST OF EUROPE LATERAL EPICONDYLITIS TREATMENT MARKET 2014-2022 ($ MILLION)
FIGURE 33 POPULATION IN RUSSIA (2015)
FIGURE 34 ASIA PACIFIC LATERAL EPICONDYLITIS TREATMENT MARKET BY REVENUE ($MILLION)
FIGURE 35 JAPAN LATERAL EPICONDYLITIS TREATMENT MARKET BY REVENUE ($MILLION) FIGURE 36 CHINA LATERAL EPICONDYLITIS TREATMENT MARKET BY REVENUE ($MILLION)
FIGURE 37 REST OF ASIA PACIFIC REGION LATERAL EPICONDYLITIS TREATMENT MARKET BY REVENUE ($MILLION)
FIGURE 38 MEA REVENUE GENERATION IN LATERAL EPICONDYLITIS TREATMENT MARKET ($MILLION)
FIGURE 39 PREFERRED THERAPEUTIC MANAGEMENT OF LATERAL EPICONDYLITIS IN MIDDLE EAST & AFRICA
FIGURE 40 CHINA LATERAL EPICONDYLITIS TREATMENT MARKET BY REVENUE ($MILLION)
FIGURE 41 PERCENTAGE OF PEOPLE OVER THE POPULATION IN LATIN AMERICA (AGE 60+ AND ABOVE)
Type of Treatment Segmentation Investigation
Based on the type of treatment the global lateral epicondylitis (tennis elbow) treatment market is segmented as follows:
Tennis elbow is disorder caused due to swelling of the tendons which leads to the pain in the arm and elbow. Repetitive motion of the arms can lead to a strain in the muscles and tendons, this can further lead to the microscopic tear of the tissues. A number of symptoms faced in daily life signals towards the lateral epicondylitis such as pain felt in doing the tasks such as lifting something, straightening the wrist or raising the hands, making grip etc. A large number of treatments are available for the conditions which include intake of Painkillers and NSAIDs, Corticosteroid injections, shock wave therapy, surgery and equipment and other products. In base year 2015, Corticosteroids injection and Painkillers & NSAIDs accounted for approximately 50% - 55% of the total market share because these are the first line therapies preferred by medical practitioners, cost effective and majorly used as supportive therapies, and most accessible source of treatment across the globe. In addition equipment and other products segment is the largest and most recommended supportive treatment against lateral epicondylitis (tennis elbow).
For the purpose of this study, the global lateral epicondylitis (tennis elbow) treatment market is categorized as follows:
The geographical segmentation of the global market for lateral epicondylitis (tennis elbow) treatment market comprises North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America. In base year 2015, North America accounted for the largest market in the lateral epicondylitis (tennis elbow) treatment market due to rising number of sport competitions & events in U.S. along with the rising awareness among the patients are the key factors contributing towards the growth of lateral epicondylitis treatment market in this region. Tennis elbow is estimated to have a prevalence of 1.3% in the overall population in North America. The incidences mainly occur around the age of 40-50 years. Growing geriatric population in the North America region is also expected to strengthen the demand for lateral epicondylitis treatment in the region. According to market experts, lateral epicondylitis treatment has a significant impact on the growth of anti-inflammatory drugs. The various anti-inflammatory drugs (NSAIDS) include cortisone, ibuprofen and aspirin. The data suggests that these are one of the widely used class of drugs, with approx. 70 million subscriptions and more than 30 billion over the counter tablets that are annually being sold in the U.S. These drugs are mainly used to control the pain of lateral epicondylitis.
